Authors
Kenneth B Margulies, Adrian F Hernandez, Margaret M Redfield, Michael M Givertz, Guilherme H Oliveira, Robert Cole, Douglas L Mann, David J Whellan, Michael S Kiernan, G Michael Felker, Steven E McNulty, Kevin J Anstrom, Monica R Shah, Eugene Braunwald, Thomas P Cappola, NHLBI Heart Failure Clinical Research Network
Publication date
2016/8/2
Journal
Jama
Volume
316
Issue
5
Pages
500-508
Publisher
American Medical Association
Description
Importance
Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.
Objective
To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.
Design, Setting, and Participants
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.
Interventions
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as …
Scholar articles
KB Margulies, AF Hernandez, MM Redfield, MM Givertz… - Jama, 2016